Search is Powered by Google
Pharma Industry / Biotech Industry News

Pharmaceutical Industry Donations About Even To Democrats, Republicans, After Years Of Favoring GOP

Main Category: Pharma Industry / Biotech Industry
Also Included In: Public Health
Article Date: 15 Oct 2008 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Campaign contributions by pharmaceutical firms to Democrats and Republicans are about equal in 2008, after the industry donated about twice as many funds to the GOP over "most of the last decade," according to campaign finance reports, the New York Times reports. In the 2008 election cycle, political action committees and employees of drugmakers have contributed $20 million to federal candidates from the two parties, with 49% going to Democrats and 51% going to Republicans, according to data compiled by the Center for Responsive Politics. According to the Times, the breakdown has not been that even since 1990. Democrats received 31% of the drug industry's campaign contributions in 2000, 26% in 2002, 34% in 2004 and 31% in 2006. The data indicate that the largest donors to political campaigns during the current election cycle have been Pfizer, Amgen and Johnson & Johnson.

According to lobbyists and pharmaceutical executives, the change is a result of the Democrats' control over both chambers of Congress and the expectation that they will expand their majorities and potentially win the White House. Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America, said, "There's a new world order." Fred DuVal, treasurer of the Democratic Governors Association, said, "Parity between the parties is now the operating principle for many corporate [PACs] in the health care industry. That's a sea change."

Another potential reason for the decrease in donations to GOP campaigns is that Republican presidential nominee Sen. John McCain (Ariz.) has proposed allowing the federal government to negotiate directly with drugmakers for lower prices for Medicare beneficiaries, a "position that is anathema to the industry," the Times reports. The Times reports that public programs account for a growing amount of the money spent on prescription drugs: 34% in 2006, compared to 23% in 2000, according to campaign finance data. Leading Democrats have proposed to further expand public involvement in the health care sector, according to the Times.

In addition, McCain supports the reimportation of drugs from Canada and some other countries, which the industry opposes. He also has supported legislation to allow low-cost generic drugs to be approved more quickly and backed a bill to codify the patient's bill of rights, which insurers and President Bush both opposed, according to the Times (Pear, New York Times, 10/14).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation.  All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
U.S. FDA Approves Requip® XL™, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
15 Jun 2008
GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease...


When Your Cycle Becomes a Major Headache
When Your Cycle Becomes a Major Headache

Cathy's gets as many as 12 to 15 headaches a month and they are all associated with her menstrual cycle. Migraines like hers tend to last longer and be more severe than other migraines. Figuring out what was triggering her headaches helped Cathy and her doctor come up with a successful treatment plan.

more videos are available in our health videos section.